Welcome to our new website. We have rebranded from Atnahs to Pharmanovia — read more
Our purpose is to progress iconic medicines for the benefit of patient health globally. We aspire to be an agile and imaginative specialty pharma business and a preferred partner for innovator pharma companies.
More about us10+
Offices
20+
Brands
140+
Markets
200+
Employees
Our key products include Inderal®, Tenormin®, Tenoretic®, Zestril®and Zestoretic®
Our key products include Bonviva®, Rocaltrol® and Synacthen®
Our key products include Anaprox®, Naprosyn®, Toradol® and Valium®
Our key products include Bondronat®, Dipentum® and Kytril®
We work with innovator pharma companies on the late stage activities of development, co-development, licensing and established brand acquisition. We aim to be open, approachable and collaborative. We pride ourselves on our entrepreneurial heritage and we retain a dynamic, motivated and “can do” attitude. We have an enviable track record and repeat transactions bear testament to our status as a preferred partner.
Basildon (UK), 20 July, 2021 – m8 Pharmaceuticals and Pharmanovia have signed an exclusive licensing agreement...
More informationAmit Patel is retiring as CEO, will transition to the Advisory Committee James Burt will take...
More informationBasildon (UK), 3 June 2021 – Pharmanovia, the original medicines specialist globally announced the promotion of...
More informationWe are an experienced group of people with a can-do attitude. We believe in openness, honesty and courtesy, and value collaboration above all else. If you are a motivated and dynamic individual, we can empower you and you will thrive with us.
We are proud to be a member of EMIG, the Ethical Medicines Industry Group.
Learn more at emig.org.uk
